MEtatastic Renal Carcinoma LINes
MERLIN
Pronostic Assessment of Mortality Among Locally Advanced or Metastatic Renal Cell Carcinoma Patients After First Line Treatment : Multicenter Prospective Cohort Study With Historic Medical Data
1 other identifier
observational
440
1 country
8
Brief Summary
The hypothesis of this study are as follows:
- Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals.
- In a routine care population, antitumour drugs may have a significant impact on overall survival through their targeted antitumor effect, but also through their toxicity profile and their impact on comorbidities.
- The optimization of patient support (supportive care, drug tolerance monitoring) can have an impact on the prognosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2018
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 15, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 3, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2019
CompletedFirst Submitted
Initial submission to the registry
April 24, 2019
CompletedFirst Posted
Study publicly available on registry
April 26, 2019
CompletedApril 30, 2019
April 1, 2019
9 months
April 24, 2019
April 26, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Overall survival after the first line of treatment
Time elapsed between initiation date for 2nd line treatment et the date of death, whatever the cause.
year 11
Eligibility Criteria
Patients with locally advanced or metastatic renal cell carcinoma, whose first-line treatment included at least one anti-angiogenic agent (tyrosine kinase inhibitor or monoclonal antibodies) and / or an mTOR inhibitor
You may qualify if:
- Patients with locally advanced or metastatic renal cell carcinoma
- Whose first-line treatment included at least one anti-angiogenic agent (tyrosine kinase inhibitor or monoclonal antibodies) and / or an mTOR inhibitor;
- Whatever was the overall ECOG-PS score (Eastern Cooperative Oncology Group Performance Status) at treatment initiation time
- With first-line treatment carried out between 2007 and June 2016.
You may not qualify if:
- Patient previously treated with only one cytokine (Interferon α2a, high-dose interleukin-2)
- Refusal of processing of personal data
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (8)
CHU de Besançon
Besançon, France
Hôpital Henri Mondor
Créteil, France
Hôpital Nord Franche-Comté Montbéliard
Montbéliard, France
Hôpital Cochin
Paris, France
Hôpital Européen Georges Pompidou
Paris, France
Hôpital Saint-Louis
Paris, France
Institut Mutualiste Montsouris
Paris, France
Hôpital d'Instruction des Armées de Bégin
Saint-Mandé, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Benoit Rousseau, MD
Henri Mondor University Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 24, 2019
First Posted
April 26, 2019
Study Start
January 15, 2018
Primary Completion
October 3, 2018
Study Completion
April 1, 2019
Last Updated
April 30, 2019
Record last verified: 2019-04
Data Sharing
- IPD Sharing
- Will not share